Washington, DC (February 24, 2014)—A recent article in JAMA Otolaryngology reported a significant over-diagnosis of thyroid cancer. The study authors found that while incidence of thyroid cancer has nearly tripled since 1975, mortality rate from thyroid cancer between 1975 and 2009 remained stable. Endocrine Society member R. Michael Tuttle, MD, an expert on thyroid cancer, is prepared to offer comment on the many questions surrounding this issue, including:
Are clinicians looking too hard for thyroid cancer?
Is “overtreatment” a problem in this patient population? What are the risks?
How do clinicians know when to pursue more aggressive therapies for thyroid cancer?
Are there any new alternative therapies for thyroid cancer on the horizon?
The Endocrine Society and its members are concerned that patients legitimately diagnosed with thyroid cancer may second-guess their endocrinologists or may interrupt their treatment.
R. Michael Tuttle, MD
Representative of the Endocrine Society
Endocrinologist, Memorial Sloan Kettering Cancer Center
Professor, Joan and Sanford I. Weill Medical College, Cornell University
Endocrine Society member R. Michael Tuttle, MD, is available to offer comment on the diagnosis and treatment of thyroid cancer.
To schedule an interview, please contact Aaron Lohr at firstname.lastname@example.org or 202-971-3654.
# # #
Founded in 1916, the Endocrine Society is the world’s oldest, largest and most active organization devoted to research on hormones and the clinical practice of endocrinology. Today, the Endocrine Society’s membership consists of over 17,000 scientists, physicians, educators, nurses and students in more than 100 countries. Society members represent all basic, applied and clinical interests in endocrinology. The Endocrine Society is based in Washington, DC. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at https://twitter.com/#!/EndoMedia.